Olfactory Neuroblastoma (Esthesioneuroblastoma): Symptoms, Diagnosis, Stages and Treatment (2026 Guide)

Medically reviewed content · Published 2026 · Last reviewed August 2026

Olfactory neuroblastoma also called esthesioneuroblastoma (ENB) — is a rare malignant tumor that arises from cells associated with the olfactory neuroepithelium, the specialized tissue in the upper nasal cavity responsible for smell. It accounts for only about 2–6% of all sinonasal tumors, making it a genuinely rare cancer. It can extend into nearby sinuses, the orbit (eye socket), or the skull base, and in more advanced cases can spread to lymph nodes in the neck or, less commonly, to distant organs. Its behavior varies considerably from patient to patient — pathology grade and anatomic stage, assessed together, are what actually determine treatment and outlook, not the diagnosis name alone.

This guide explains what olfactory neuroblastoma is, how it’s diagnosed and graded, current treatment approaches — including endoscopic skull-base surgery, craniofacial resection, radiation, and the more limited role of chemotherapy — and what treatment for this rare cancer looks like for international patients considering care in India. This is general medical education, not a diagnosis or an individual treatment recommendation.

Is Olfactory Neuroblastoma the Same as Neuroblastoma?

No — despite the similar name, these are different diseases. Olfactory neuroblastoma (esthesioneuroblastoma) is a rare cancer of the nasal cavity, arising from olfactory neuroepithelial cells, and occurs across a wide age range including adults. Neuroblastoma is a different cancer that arises from the sympathetic nervous system, most commonly in the adrenal glands or abdomen, and overwhelmingly affects young children.

The two share a name because both arise from neural-crest-related cells at a microscopic level, but they are biologically distinct, present differently, are staged differently, and are treated by entirely different specialist teams. If you’ve been told a diagnosis of “olfactory neuroblastoma,” it is not the childhood cancer more commonly known simply as “neuroblastoma.”

Olfactory neuroblastoma should also be distinguished from other sinonasal cancers that can look similar on imaging — including sinonasal neuroendocrine carcinoma, sinonasal undifferentiated carcinoma, and squamous cell carcinoma of the nasal cavity. These are managed differently, which is why accurate pathology review, discussed below, is essential rather than optional.

How Common Is Olfactory Neuroblastoma, and Who Gets It?

Olfactory neuroblastoma is rare, representing roughly 2–6% of sinonasal tumors — sinonasal tumors themselves are an uncommon category of cancer overall. Because the disease is rare, precise incidence figures vary between studies and reporting registries, and you may see somewhat different numbers cited in different sources. It has often been described as having a bimodal age distribution — occurring somewhat more often around the second decade of life and again around the sixth decade — but individual studies show real variation in this pattern, and the disease can occur at essentially any age, in both males and females.

Causes and Risk Factors

The exact cause of olfactory neuroblastoma is not established, and most patients have no identifiable preventable cause. Evidence for specific environmental or occupational risk factors is considerably more limited than it is for common cancers like lung or colorectal cancer — there is no well-established link to smoking or a specific occupational exposure in the way there is for some other sinonasal or head and neck cancers.

This guide will not speculate beyond the current evidence base: if you’re looking for something you did that caused this, the honest answer for most patients is that there isn’t one to find.

Symptoms of Olfactory Neuroblastoma

Symptoms often resemble common nasal or sinus conditions, which is part of why diagnosis can be delayed. Potential symptoms include:

• Persistent nasal obstruction, often one-sided
• Recurrent nosebleeds (epistaxis)
• Reduced or lost sense of smell
• Persistent nasal discharge
• Facial pressure or pain
• Headache
• Watery eyes
• Vision changes, in more advanced disease
• Facial swelling
• Neurologic symptoms, in advanced skull-base or intracranial disease

None of these symptoms are specific to olfactory neuroblastoma — they are far more commonly caused by benign conditions like chronic sinusitis, nasal polyps, or allergic rhinitis. The pattern that generally warrants evaluation is persistence and progression, not any single symptom in isolation.

When should persistent nasal symptoms be evaluated?

Medical evaluation is generally appropriate when nasal symptoms are persistent (lasting well beyond a typical cold or sinus infection), one-sided rather than affecting both nostrils equally, progressively worsening, or accompanied by recurrent unexplained nosebleeds, a new reduction in smell, facial swelling, or any vision or neurologic symptoms. This does not mean these symptoms indicate cancer — the overwhelming majority of persistent nasal symptoms have benign causes — but this combination is what typically prompts an ENT referral for closer evaluation.

Can loss of smell be a symptom?

Yes. Because the tumor arises from and can affect the olfactory neuroepithelium directly, reduced or absent sense of smell (anosmia or hyposmia) can be an early symptom. However, smell loss has many far more common causes — including chronic sinusitis, nasal polyps, viral upper respiratory infections, and normal aging — and anosmia alone does not confirm or even meaningfully suggest this diagnosis. It’s one symptom among several that, in combination and when persistent, warrants ENT evaluation.

How Olfactory Neuroblastoma Is Diagnosed

1. Medical history and ENT examination
2. Nasal endoscopy
3. CT imaging
4. MRI
5. Biopsy
6. Histopathology and immunohistochemistry
7. Hyams grade assessment
8. Staging (Kadish/modified Kadish and/or TNM)
9. Multidisciplinary treatment planning

Nasal endoscopy

An ENT specialist examines the nasal cavity using a thin, lighted endoscope passed through the nostril. Olfactory neuroblastoma typically appears as a mass in the superior (upper) nasal cavity, near the olfactory region. Endoscopy helps determine the location and visible extent of the tumor and identifies suspicious tissue for biopsy — it’s usually the first direct look a specialist gets at the tumor itself, though it doesn’t show extension beyond what’s directly visible.

CT and MRI

CT is particularly useful for evaluating bone destruction, detailed sinonasal anatomy, and skull-base bony changes. MRI is particularly useful for evaluating soft tissue detail, skull-base involvement, intracranial extension, orbital involvement, and spread along nerves or adjacent soft tissue. CT and MRI provide complementary information rather than one replacing the other — most complete pre-treatment workups include both. PET/CT may be added when there’s concern about lymph node involvement, distant metastasis, or to help evaluate possible recurrence, though it isn’t a universal requirement for every patient — its use depends on the clinical situation and the specialist team’s judgment.

Biopsy and pathology

A biopsy is required to establish the diagnosis — typically obtained endoscopically during the same procedure used for initial examination. This can be genuinely challenging: several sinonasal tumors can look similar to each other on both imaging and initial pathology review, which is why specialist head-and-neck pathology review is particularly valuable for this rare tumor rather than a general pathology read alone.

Pathology evaluates tumor architecture, cell morphology, differentiation, neuroendocrine and neural marker expression, mitotic activity, and necrosis. Immunohistochemistry — using markers including synaptophysin, chromogranin, CD56, S100, and SOX10 — helps confirm the diagnosis and distinguish esthesioneuroblastoma from other sinonasal tumors it can resemble; a characteristic finding is S100-positive sustentacular (supporting) cells at the periphery of tumor cell nests. No single marker establishes the diagnosis alone — pathologists interpret the full immunohistochemical panel together with tumor architecture.

Hyams Grading: What It Means

Hyams grade is the most widely used histologic grading system for olfactory neuroblastoma, assessing features under the microscope that correlate with biological behavior: tumor architecture (how organized the cell arrangement is), the presence of a fibrillary background, rosette formation, nuclear features, mitotic activity, and necrosis. Grades range from I (most differentiated, most favorable histologic appearance) to IV (least differentiated, most aggressive appearance).

Research published in 2025 examining Hyams grade specifically confirmed that high grade (III–IV) is an independent predictor of worse overall survival, progression-free survival, and distant-metastasis-free survival, even after accounting for anatomic stage — meaning grade adds real, independent information beyond what stage alone tells you. That said, grade alone does not determine prognosis for an individual patient; it’s assessed together with stage, extent of disease, and treatment response.

Staging: Kadish and TNM Systems

Olfactory neuroblastoma has historically been staged using the Kadish system, based on anatomic extent as seen on CT and MRI:

Reported 5-year survival by original Kadish stage has been cited as roughly 75% for Stage A, 68% for Stage B, and 41% for Stage C in pooled data — though these figures come from combining many years and treatment approaches across different studies, and outcomes with current treatment for an individual patient can differ meaningfully from these pooled historical numbers.

Because the original Kadish system doesn’t account for tumor grade or fully capture how locally advanced some Stage C tumors are, several modifications and alternative systems are also used, including the modified Kadish-Morita system (which adds Stage D for metastatic disease, as shown above) and the Dulguerov TNM system, which separately describes the primary tumor’s extent (T), lymph node involvement (N), and distant metastasis (M) in more granular detail than Kadish alone provides.

Current research has also been actively working to incorporate Hyams grade directly into staging systems, since grade has been shown to meaningfully improve how well a staging system predicts individual outcomes. Because several staging systems are in active clinical use and none has become a single universal standard, your specialist team will tell you which system (or combination) they’re using and what your specific stage means under that system — don’t assume a stage letter or number means the same thing across different systems without checking.

Olfactory Neuroblastoma Treatment Overview

Because olfactory neuroblastoma is rare, there is no single universal treatment protocol, and management is generally guided by accumulated case series and expert consensus rather than the large randomized trials available for more common cancers. Treatment depends on Hyams grade, Kadish/TNM stage, extent of skull-base involvement, orbital or intracranial extension, cervical lymph node involvement, distant metastases, resectability, and overall health.

Given the complexity of skull-base anatomy involved, this tumor is generally best managed by a multidisciplinary team — typically including a head-and-neck surgeon, skull-base surgeon, neurosurgeon, ENT/rhinologist, radiation oncologist, medical oncologist, neuroradiologist, and a head-and-neck pathologist experienced with this specific tumor type. Coordination between these specialists, rather than any single specialist working alone, is what typically produces the best-planned treatment for this anatomically complex disease.

Surgery

Complete surgical removal with clear margins is a central treatment principle for resectable disease. The surgical approach depends heavily on tumor location and extent:

• Endoscopic endonasal/skull-base surgery — accesses the tumor through the nasal passages, avoiding external incisions, and can provide direct visualization of the tumor and skull base for tumors with an anatomy suited to this approach. It is not automatically appropriate for every tumor — suitability depends on the specific extent of disease, particularly around the orbit and brain.
• Open craniofacial resection — an open surgical approach combining access through the skull and face, generally reserved for tumors with more extensive skull-base or intracranial involvement not safely addressable endoscopically. This remains an important, current technique for appropriately selected advanced tumors — it has not become outdated, even as endoscopic techniques have expanded.
• Combined approaches, using both endoscopic and open/transcranial access, are used for select complex tumors, sometimes in coordination with neurosurgery.

Surgical goals include complete tumor removal when feasible, appropriate oncologic margins, preservation of critical structures (vision, brain function) where safely possible, and secure skull-base reconstruction to prevent complications like cerebrospinal fluid leak. Complete removal cannot be guaranteed in advance of surgery for every tumor — this depends on the tumor’s actual anatomic relationship to critical structures, which is sometimes only fully clear during the operation itself.

Radiation therapy

It is commonly used after surgery, especially for positive or close margins, more advanced local disease, or higher Hyams grade, and can also be used as part of definitive treatment in selected cases, for recurrent disease, or for palliation. Radiation planning for this tumor is genuinely complex because of its proximity to the brain, eyes, optic nerves, optic chiasm, and other cranial nerves — treatment planning must carefully balance adequate tumor coverage against the risk to these adjacent structures.

Proton therapy may be considered for selected skull-base and sinonasal tumors because its physical dose-distribution characteristics can potentially reduce radiation exposure to some surrounding critical tissues compared to conventional photon radiation. This is a genuine potential advantage in appropriately selected cases, but availability varies significantly between centers, and proton therapy is not automatically superior for every patient — the decision depends on the specific tumor’s location relative to critical structures and should be made by the treating radiation oncology team, not assumed as a default upgrade.

Chemotherapy

Chemotherapy has a more selective role than surgery and radiation for many localized olfactory neuroblastomas, reflecting the fact that evidence specific to this rare disease is more limited than for common cancers. Potential roles include neoadjuvant (before other treatment) use in selected advanced disease — one published series reported a 15-year disease-free survival of over 80% using neoadjuvant chemotherapy followed by radiation for advanced Kadish Stage C tumors — concurrent or combined treatment in selected cases, and treatment of recurrent or metastatic disease. Because evidence is limited by the disease’s rarity, chemotherapy decisions in this setting tend to be individualized more heavily than in common cancers with large randomized trials to draw on.

Advanced or Locally Extensive Disease

Intracranial extension: Because olfactory neuroblastoma originates close to the skull base, more advanced tumors can extend intracranially. This is different from distant metastasis — intracranial extension means the tumor has grown directly into the space near or within the brain from its origin site, not that it has spread to a separate distant location. Treatment for this pattern generally requires skull-base surgery in close neurosurgical collaboration, along with carefully planned radiation; MRI is particularly important for evaluating the extent of this involvement before treatment planning.

Orbital involvement: More advanced tumors can extend toward the orbit (eye socket), potentially causing visual changes, abnormal eye movement, or swelling around the eye. Whether the orbit and eye can be preserved depends on the specific extent of involvement — orbital involvement does not automatically require removal of the eye, and preserving vision and orbital structures where oncologically safe is generally a treatment priority.

Cervical lymph node metastases: The tumor can spread to lymph nodes in the neck. Management may involve neck dissection (surgical removal of affected lymph node regions), radiation to the neck, or systemic therapy, depending on the extent of nodal disease and the overall treatment strategy — there is no single universal approach applied to every case of nodal involvement.

Recurrent and Metastatic Disease

Recurrence can occur locally (at or near the original site), in the skull base, in cervical lymph nodes, or at distant sites — and importantly, recurrence in olfactory neuroblastoma can occur years after initial treatment, which is why long-term follow-up (discussed below) matters more for this tumor than for many other cancers. Treatment for recurrence depends on where it occurs, what treatment was given previously, how much time has passed, whether the recurrence is resectable, whether there’s distant disease, and overall health — options include salvage surgery, re-irradiation in selected cases, systemic therapy, or combined approaches.

Distant metastases, when they occur, most often involve the lungs, bones, or liver. Treatment may involve systemic therapy, radiation directed at specific metastatic sites, surgery in selected circumstances, or palliative and supportive care focused on symptom control and quality of life. Distant disease is not automatically terminal — treatment approach and realistic goals depend heavily on the extent and location of metastatic spread, the tumor’s grade, and how it responds to treatment.

Prognosis and Survival

Prognosis depends on Kadish/TNM stage, Hyams grade, extent of local disease, lymph node involvement, distant metastases, surgical margin status, response to radiation, and whether recurrence occurs. Because olfactory neuroblastoma is rare, survival estimates vary considerably between studies — a recent large multicenter analysis found generally favorable 5-year overall survival across the modern-era cohort studied, with higher Hyams grade and more advanced modified staging both independently associated with a greater likelihood of disease progression. Older pooled data has cited roughly 75%, 68%, and 41% five-year survival for Kadish Stages A, B, and C respectively, though these numbers combine multiple decades of differing treatment approaches and shouldn’t be read as a precise prediction for a patient treated with current techniques.

No source can honestly give you a single survival percentage that applies to your specific situation — an individual’s outlook depends on the combination of your own stage, grade, treatment response, and overall health, assessed together by your treating team, not any statistic from a published study population.

Long-Term Follow-Up

Because recurrence in olfactory neuroblastoma can occur years after initial treatment — a genuinely distinguishing feature of this disease compared to many other cancers — long-term follow-up is important well beyond the typical 2-3 year window used for many other tumors. Follow-up generally includes regular ENT examination and nasal endoscopy, MRI or CT imaging where clinically indicated, ongoing assessment of symptoms, and evaluation of the neck or distant sites when there’s specific concern. Your specialist team will set a surveillance schedule tailored to your specific stage, grade, and treatment history — there is no single universal follow-up interval that applies to every patient.

Quality of life and treatment effects

Depending on the specific treatment approach, patients may experience reduced sense of smell (which can result from the tumor itself or from treatment), nasal dryness or crusting, ongoing sinus symptoms, effects on vision if the orbit was involved or treated, hormonal or endocrine effects after skull-base radiation in some cases, fatigue, and other treatment-related effects. These risks and their likelihood depend substantially on which specific treatment approach was used — your treating team can describe the specific effects relevant to your own treatment plan.

Olfactory Neuroblastoma Treatment Cost in India

Because olfactory neuroblastoma is a genuinely rare cancer, there is very little published, disease-specific cost data for India — unlike more common cancers, dedicated pricing pages for this exact tumor essentially don’t exist in a reliable form. Rather than presenting borrowed figures from more common head-and-neck cancers as though they specifically apply to this tumor, it’s more honest to say plainly: cost for this condition needs to be estimated individually, based on your specific case, more than for almost any other topic covered in this guide.

What we can say responsibly, based on the general cost structure of comparable skull-base and head-and-neck cancer care in India, is that total cost will depend on:

• ENT/skull-base specialist consultation and initial workup
• Nasal endoscopy
• CT and MRI (and PET/CT, if indicated)
• Biopsy, histopathology, and immunohistochemistry, ideally with specialist head-and-neck pathology review
• Surgery — with endoscopic skull-base procedures, open craniofacial resection with reconstruction, and cases requiring neurosurgical involvement representing meaningfully different cost tiers from each other
• Radiation therapy, including proton therapy specifically if that approach is recommended and available
• Chemotherapy, if used
• Hospitalization length and any management of complications
• Follow-up imaging over the required long-term surveillance period

Given how much these components vary by the specific surgical approach and whether neurosurgical or reconstructive involvement is needed, request a written, itemized quote based on your own imaging, pathology, and proposed treatment plan rather than relying on any general cost figure including any borrowed from more common head-and-neck cancer pricing — for this specific, rare tumor.

Why International Patients Consider India for Olfactory Neuroblastoma Care, and How to Choose a Center

India has centers with genuine skull-base surgery, head-and-neck oncology, and neurosurgical expertise, alongside advanced imaging and radiation oncology infrastructure — for international patients, the appeal is typically this combination with costs generally lower than the US, UK, or much of Europe. Because this tumor is rare, however, the most important factor in choosing a center isn’t “is it in India” or general hospital reputation — it’s whether the specific center and surgeon have real, demonstrable experience with this exact tumor type, since skull-base tumors of this kind are managed quite differently from more common head-and-neck cancers.

When evaluating a center for olfactory neuroblastoma in India or anywhere look for:

• A head-and-neck oncologist and skull-base surgeon with specific experience in sinonasal/anterior skull-base tumors, not general ENT oncology alone
• Neurosurgical collaboration readily available for cases with intracranial extension
• A head-and-neck pathologist experienced with sinonasal tumor differential diagnosis
• MRI and CT capability, with PET/CT access where needed
• Advanced radiation oncology, including proton therapy access if your specific case may benefit from it
• Reconstruction/plastic surgery capability for skull-base reconstruction
• A genuine multidisciplinary tumor board reviewing skull-base cases specifically
• Established international patient services (visa letters, coordination, interpreter support)

Ask directly about the center’s case volume and outcomes for this specific tumor type — not just general cancer or general head-and-neck cancer volume — and verify surgeon and center credentials independently rather than relying on third-party “top hospital” rankings, which are common in this space and don’t substitute for direct verification.

The International Patient Treatment Journey

1. Share existing medical reports and imaging for review
2. Obtain pathology review, ideally by an experienced head-and-neck pathologist
3. Confirm diagnosis and determine Hyams grade
4. Determine Kadish/modified Kadish and/or TNM stage
5. Assess skull-base, orbital, and intracranial extension in detail
6. Multidisciplinary specialist review
7. Treatment plan developed, with alternatives explained
8. Hospital and specialist confirmation
9. Written, itemized cost estimate
10. Medical visa guidance
11. Travel and accommodation arrangements
12. Treatment delivery
13. Recovery and monitoring
14. Long-term follow-up planning
15. Remote follow-up and report-sharing with the home-country physician

No credible provider can guarantee a diagnosis, surgical eligibility, complete tumor removal, cure, treatment response, an exact final cost, visa approval, or survival outcome before reviewing a patient’s actual imaging and pathology — be cautious of any provider offering these guarantees upfront, particularly for a tumor this anatomically complex.

Questions to Ask Your Olfactory Neuroblastoma Team

• Has the pathology been reviewed by an experienced head-and-neck pathologist?
• What is the Hyams grade?
• What is the Kadish (or modified Kadish) stage, and/or TNM stage?
• Is the tumor confined to the nasal cavity, or has it entered the sinuses, skull base, orbit, or intracranially?
• Are cervical lymph nodes involved? Is there distant disease?
• Is complete surgical removal realistically possible?
• Would endoscopic skull-base surgery be appropriate, or is open craniofacial surgery necessary?
• Is radiation recommended, and would proton therapy offer a meaningful advantage in my specific case?
• Is chemotherapy necessary for my situation?
• What is the goal of treatment?
• What are the specific risks to my vision and brain structures with the proposed approach?
• What will the long-term follow-up plan look like, and for how many years?
• What happens if the tumor returns?

How Shifam Health Helps International Olfactory Neuroblastoma Patients

Shifam Health is a medical tourism facilitator, not a cancer hospital, ENT clinic, skull-base surgery center, or pathology laboratory — we don’t diagnose olfactory neuroblastoma or determine treatment plans. Given how rare and anatomically complex this tumor is, what we focus on is helping international patients connect with genuinely experienced skull-base and head-and-neck oncology teams: coordinating the review of imaging and pathology by relevant specialists, helping identify hospitals with real, verifiable experience in sinonasal/skull-base tumors specifically, obtaining written treatment and cost estimates, assisting with medical visa documentation, arranging airport pickup and accommodation, providing interpreter support where needed, and staying in touch for follow-up communication once you return home.

If you or someone you’re caring for has received this diagnosis, share your available reports with our team on WhatsApp or through a quick inquiry form — there’s no obligation, and we typically respond within 24 hours.

Frequently Asked Questions

Conclusion

Olfactory neuroblastoma is a rare, anatomically complex cancer where Hyams grade and anatomic stage — assessed together, not separately — determine what a specific diagnosis actually means and which combination of surgery, radiation, and, in selected cases, chemotherapy is appropriate.

Because it’s rare enough that few patients or families have prior familiarity with it, and because recurrence can occur years after treatment, getting an accurate pathology review and a genuinely experienced multidisciplinary skull-base team involved early matters more here than for many more common cancers. If you or someone you’re caring for has received this diagnosis, confirming your Hyams grade and stage, and asking direct questions about your specific treatment team’s experience with this exact tumor, is the most useful step before deciding on a treatment path, in India or anywhere else.

This article is for general medical education and does not replace individualized advice from a qualified head-and-neck oncologist, skull-base surgeon, or radiation oncologist. It is not a diagnosis, treatment recommendation, or guarantee of any outcome.